465 results match your criteria Cancer Chemother Biol Response Modif[Journal]


Native and genetically engineered anti-disialoganglioside monoclonal antibody treatment of melanoma.

Cancer Chemother Biol Response Modif 2005 ;22:789-97

University of Wisconsin Comprehensive Cancer Center, Madison, WI 53792, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22037-3DOI Listing
October 2005
4 Reads

Human tumor associated antigen mimicry by xenoantigens, anti-idiotypic antibodies and peptide mimics: implications for immunotherapy of malignant diseases.

Cancer Chemother Biol Response Modif 2005 ;22:769-87

Department of Immunology, Roswell Park Cancer Institute, Buffalo, NY 14263, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22036-1DOI Listing
October 2005
7 Reads

DNA vaccines for melanoma.

Cancer Chemother Biol Response Modif 2005 ;22:761-8

Department of Medicine, Memorial Sloan-Kettering Cancer Center, Weill Medical College of Cornell University, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22035-xDOI Listing
October 2005
4 Reads

Immunizing against partially defined antigen mixtures, gangliosides, or peptides to induce antibody, T cell, and clinical responses.

Cancer Chemother Biol Response Modif 2005 ;22:749-60

Department of Medicine & Swim Across America Laboratory, Memorial Sloan Kettering Cancer Center, New York, NY, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22034-8DOI Listing
October 2005
6 Reads

Chemotherapy, cytokines, and biochemotherapy for melanoma.

Authors:
Omar Eton

Cancer Chemother Biol Response Modif 2005 ;22:739-48

Department of Melanoma, Division of Cancer Medicine, Univerity of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
October 2005
27 Reads

Current status of interferon-alpha in the treatment of melanoma.

Cancer Chemother Biol Response Modif 2005 ;22:729-37

Department of Surgical Oncology, Erasmus University Medical Center--Daniel den Hoed Cancer Center, Rotterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22032-4DOI Listing
October 2005

Genetics, prevention and screening for melanoma.

Authors:
Diane Hershock

Cancer Chemother Biol Response Modif 2005 ;22:707-28

Department of Hematology/Oncology, Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA 19104, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22031-2DOI Listing
October 2005
1 Read

AIDS-associated malignancies.

Cancer Chemother Biol Response Modif 2005 ;22:687-706

Department of Oncology, Chelsea & Westminster Hospital, London, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22030-0DOI Listing
October 2005
1 Read

Supportive care.

Authors:
Maurie Markman

Cancer Chemother Biol Response Modif 2005 ;22:677-86

M D Anderson Cancer Center, Houston, TX 77030, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22029-4DOI Listing
October 2005
1 Read

Biology and therapy of malignant solid tumors in childhood.

Cancer Chemother Biol Response Modif 2005 ;22:643-76

Department of Paediatric Oncology, Emma Children's Hospital, Academic Medical Centre, University of Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22028-2DOI Listing
October 2005
2 Reads

Central nervous system tumors.

Cancer Chemother Biol Response Modif 2005 ;22:605-41

Barrow Neurological Institute, Phoenix, AZ 85013, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22027-0DOI Listing
October 2005
4 Reads

Soft-tissue and bone sarcomas.

Cancer Chemother Biol Response Modif 2005 ;22:591-604

Department of Cancer Therapeutics, Institute of Cancer Research, Belmont, Sutton Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22026-9DOI Listing
October 2005
4 Reads

Melanoma.

Cancer Chemother Biol Response Modif 2005 ;22:563-90

The University of Pittsburgh, Cancer Institute, Melanoma Center, Pittsburgh, PA 15213-2584, USA.

View Article

Download full-text PDF

Source
October 2005
6 Reads

Breast cancer.

Cancer Chemother Biol Response Modif 2005 ;22:545-61

Department of Medicine, Breast Unit, Royal Marsden Hospital, London, UK.

View Article

Download full-text PDF

Source
October 2005
7 Reads

Systemic therapy for gynecological neoplasms: ovary, cervix, and endometrium.

Cancer Chemother Biol Response Modif 2005 ;22:515-44

Department of Obstetrics & Gynaecology, University of Brescia, Italy.

View Article

Download full-text PDF

Source
October 2005
1 Read

Genitourinary malignancies.

Cancer Chemother Biol Response Modif 2005 ;22:485-513

Department of Urologic Oncology, Anschuz Cancer, Aurora, CO 80010, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22022-1DOI Listing
October 2005
3 Reads

Neuroendocrine tumours.

Cancer Chemother Biol Response Modif 2005 ;22:471-83

Department of Endocrine Oncology, University Hospital, Uppsala, Sweden.

View Article

Download full-text PDF

Source
October 2005
10 Reads

Cancers of the large bowel and hepatobiliary tract.

Cancer Chemother Biol Response Modif 2005 ;22:443-69

University of Pennsylvania Cancer Center, Philadelphia, PA 19104-4283, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22020-8DOI Listing
October 2005
4 Reads

Lung cancer.

Cancer Chemother Biol Response Modif 2005 ;22:413-42

Division of Medical Oncology, Vrijie Universiteit Medical Center, Amsterdam and Martini Hospital , Groningnen, Amsterdam, The Netheslands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22019-1DOI Listing
October 2005
1 Read

Head and neck cancers.

Cancer Chemother Biol Response Modif 2005 ;22:401-11

Wayne State University, Wm. Beaumont Hospital, Royal Oak, MI 48073, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22018-xDOI Listing
October 2005
5 Reads

Lymphomas.

Cancer Chemother Biol Response Modif 2005 ;22:391-9

Department of Medical Oncology and Hematology, Istituto Clnico Humanitas, Milano, Italy.

View Article

Download full-text PDF

Source
October 2005
5 Reads

Plasma cell dyscrasias and leukemias.

Authors:
Peter H Wiernik

Cancer Chemother Biol Response Modif 2005 ;22:343-89

Our Lady of Mercy Cancer Center, New York Medical College, Bronx 10466, USA.

View Article

Download full-text PDF

Source
October 2005
3 Reads

Cancer therapy-induced immune modulation.

Cancer Chemother Biol Response Modif 2005 ;22:325-41

View Article

Download full-text PDF

Source
October 2005
10 Reads

T-cell genetic modification for re-directed tumor recognition.

Cancer Chemother Biol Response Modif 2005 ;22:293-324

Cancer Immunotherapeutic Program, City of Hope NCI-Designated Comprehensive Cancer Center, Duarte, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22014-2DOI Listing
October 2005
27 Reads

Retargeting T cells and immune effector cells with bispecific antibodies.

Cancer Chemother Biol Response Modif 2005 ;22:273-91

Immunotherapy Program, Adele R. Deof Cancer Center, Roger Williams Hospital, Providence, RI 02908, USA.

The development of BiAbs for therapeutic applications in cancer shows promise. As our understanding of effector cell receptor biology for triggering of cytotoxic functions improves and the behavior of TAA and the targeting antibody engagement is elucidated, customized BiAb reagents can be engineered to optimize in vivo or ex vivo arming of T cells for targeting tumors. Additionally, other variables that require consideration in the equation for successful T cell immunotherapy include: the type of effector cells, their state of activation, the type of effector receptor being activated or tareeted. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22013-0DOI Listing
October 2005
6 Reads

Systemic therapy for renal cell carcinoma.

Cancer Chemother Biol Response Modif 2005 ;22:263-72

Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22012-9DOI Listing
October 2005
9 Reads

Prostate cancer antigens and vaccines, preclinical developments.

Authors:
Douglas G McNeel

Cancer Chemother Biol Response Modif 2005 ;22:247-61

Department of Medicine, University of Wisconsin, K4/518 Clinical Science Center, Madison, WI 53792, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22011-7DOI Listing
October 2005
3 Reads

Angiogenesis pathway inhibitors.

Cancer Chemother Biol Response Modif 2005 ;22:225-45

Department of Cancer Biology, Radiation, University of Texas, MD Anderson Cancer Center, Houston, TX 70030-4009, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22010-5DOI Listing
October 2005
3 Reads

Epidermal growth factor receptor pathway inhibitors.

Cancer Chemother Biol Response Modif 2005 ;22:205-23

Medical Oncology Service, Vall d'Hebron University Hospital, Universitat Autonoma de Barcelona, Spain.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22009-9DOI Listing
October 2005
4 Reads

DNA-binding agents.

Authors:
Yago Nieto

Cancer Chemother Biol Response Modif 2005 ;22:163-203

University of Colorado Bone Marrow Transplant Program, Denver, CO 80262, USA.

View Article

Download full-text PDF

Source
October 2005
1 Read

Cyclin-dependent kinases as targets for cancer therapy.

Cancer Chemother Biol Response Modif 2005 ;22:135-62

Department of Medicine, Division of Solid Tumor Oncology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22007-5DOI Listing
October 2005
4 Reads

Farnesyltransferase inhibitors.

Authors:
Alex A Adjei

Cancer Chemother Biol Response Modif 2005 ;22:123-33

Division of Medical Oncology, Mayo Clinic, Rochester, MN 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22006-3DOI Listing
October 2005
1 Read

Topoisomerase II inhibitors.

Cancer Chemother Biol Response Modif 2005 ;22:101-21

Vanderbilt/Ingram Cancer Center, Vanderbilt University, Nashville, TN 37232, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22005-1DOI Listing
October 2005
4 Reads

Recent developments in the clinical activity of topoisomerase-1 inhibitors.

Cancer Chemother Biol Response Modif 2005 ;22:61-100

View Article

Download full-text PDF

Source
October 2005
5 Reads

Tubulin-targeting agents.

Cancer Chemother Biol Response Modif 2005 ;22:35-59

UMDNJ/Robert Wood Johnson Medical School, Department of Medicine, The Cancer Institute of New Jersey, New Brunswick 08901-1914, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(04)22003-8DOI Listing
October 2005
4 Reads

Anthracyclines.

Cancer Chemother Biol Response Modif 2005 ;22:19-33

Department of Pharmacology and Therapeutics, The Montreal Center for Experimental Therapeutics in Cancer, Sir Mortimer B Davis--Jewish General Hospital, Montréal, Québec, Canada.

View Article

Download full-text PDF

Source
October 2005
2 Reads

Thymidylate synthase inhibitors.

Cancer Chemother Biol Response Modif 2005 ;22:1-18

University of Texas Health Science Center, San Antonio Cancer Therapy & Research Center, San Antonio, TX 78229, USA.

View Article

Download full-text PDF

Source
October 2005
15 Reads

Liver directed therapies for colorectal cancer.

Cancer Chemother Biol Response Modif 2003 ;21:831-43

Division of General Surgery, H4/724 Clinical Science Center, Madison, WI 53792-7375, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(03)21040-1DOI Listing
September 2004
4 Reads

New drugs for colorectal cancer.

Cancer Chemother Biol Response Modif 2003 ;21:817-29

Center for Clinical Studies in Cancer, Albert Einstein Hospital, Sao Paulo, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(03)21039-5DOI Listing
September 2004
1 Read

Combined modality therapy for rectal cancer.

Authors:
Bruce D Minsky

Cancer Chemother Biol Response Modif 2003 ;21:803-16

Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(03)21038-3DOI Listing
September 2004
2 Reads

Molecular predictors of prognosis and response to therapy in colorectal cancer.

Cancer Chemother Biol Response Modif 2003 ;21:791-801

Washington University School of Medicine, Department of Medicine, St Louis, MO 63110-1093, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(03)21037-1DOI Listing
September 2004
4 Reads

Non-steroidal anti-inflammatory drugs (NSAIDs) for colorectal cancer prevention.

Cancer Chemother Biol Response Modif 2003 ;21:759-89

National Cancer Institute, Division of Cancer Prevention, Bethesda, MD 20892-7317, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(03)21036-xDOI Listing
September 2004
2 Reads

Risk assessment and screening for colorectal cancer.

Authors:
Karen E Kim

Cancer Chemother Biol Response Modif 2003 ;21:747-57

Section of Gastroenterology, University of Chicago, IL 60637, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(03)21035-8DOI Listing
September 2004
1 Read

AIDS-associated malignancies.

Cancer Chemother Biol Response Modif 2003 ;21:717-46

The Ohio State University, Columbus 43210, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(03)21034-6DOI Listing
September 2004
5 Reads

Supportive care.

Authors:
Maurie Markman

Cancer Chemother Biol Response Modif 2003 ;21:709-16

Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, OH 44195, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(03)21033-4DOI Listing
September 2004
1 Read

Biology and therapy of malignant solid tumors in childhood.

Cancer Chemother Biol Response Modif 2003 ;21:683-707

Department of Paediatric Oncology, Emma Children's Hospital, Academic Medical Centre, University of Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(03)21032-2DOI Listing
September 2004
1 Read

Brain tumors.

Cancer Chemother Biol Response Modif 2003 ;21:655-81

Barrow Neurological Institute, Department of Neurology, Phoenix, Arizona 85013, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(03)21031-0DOI Listing
September 2004
6 Reads

Sarcoma.

Cancer Chemother Biol Response Modif 2003 ;21:637-53

Department of Cancer Therapeutics, Institute of Cancer Research, Belmont, Surrey, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(03)21030-9DOI Listing
September 2004
10 Reads

Melanoma--new developments in diagnosis and therapy.

Cancer Chemother Biol Response Modif 2003 ;21:609-36

DIAID, Department of Dermatology, University of Vienna Medical School, Austria.

View Article

Download full-text PDF

Source
September 2004
1 Read

Breast cancer.

Cancer Chemother Biol Response Modif 2003 ;21:585-608

Istituto Nazionale Tumori, Milano, Italy.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/s0921-4410(03)21028-0DOI Listing
September 2004
4 Reads